FNDC5 and myeloid sarcoma: In the context of immune-mediated inflammation and neurodegenerative diseases such as multiple sclerosis (MS), Irisin holds potential for MS therapy by enhancing Treg functionality, thereby inhibiting the migration of effector T cells and autoreactive T cells into the central nervous system and consequently reducing myelin damage caused by these cells [7].